have ever had an allergic reaction to hydroxocobalamin or any other medicine
Patients who would like a broader introduction to medication-based treatment can also read our article on medical weight loss with medication and obesity care
Glucagon-like Peptide-1 (GLP-1) Agonists Recent Developments In June 2026, Viking Therapeutics announced on June 24 the initiation of its Phase 1 clinical trial evaluating VK3019, an investigational dual amylin and calcitonin receptor agonist (DACRA)
The studys investigator, Henning Bliddal, MD, is intrigued by whether or not theres a specific action of GLP-1 receptor agonists on the joint, not through weight loss but by itself. In addition to pain and weight reduction, those studied also had improved WOMAC physical function scores from baseline
However, copper balance matters
Hear From Our Medical Weight Loss Patients "Dr